Pesticides & Agrochemicals · Founded 1985 · www.dhanuka.com · BSE 507717 · NSE DHAN AGRI · ISIN INE435G01025
No Notes Added Yet
Business
Dhanuka Agritech Ltd. is an Indian agrochemical company engaged in the manufacturing, formulation, and marketing of a wide range of crop protection products. Its core business involves developing, registering, and distributing insecticides, herbicides, fungicides, plant growth regulators (PGRs), and public health products. The company primarily focuses on generic formulations, sourcing technicals from both domestic and international markets, and then formulating them into finished products. It generates revenue by selling these agrochemical solutions directly to farmers through an extensive pan-India distribution network, aiming to improve agricultural productivity and crop yield.
Revenue Mix
Dhanuka Agritech's revenue primarily stems from the sale of its formulated agrochemical products. While precise percentages fluctuate and are not always segmented externally with granular detail, the main product categories contributing to revenue are:
Insecticides: Products designed to control insect pests.
Herbicides: Products used to control weeds.
Fungicides: Products applied to control fungal diseases in crops.
Plant Growth Regulators (PGRs) & Others: Speciality products that influence plant growth and development, along with some public health and other niche offerings.
Herbicides and insecticides typically form a significant portion of the company's sales mix, reflecting common farmer needs for crop protection.
Industry
The Indian Pesticides & Agrochemicals industry is characterized by its dependence on monsoons and agricultural cycles, regulatory oversight, and intense competition. It comprises global multinational corporations (MNCs) bringing patented molecules and a large number of domestic players focusing on generic formulations. Dhanuka Agritech is one of the established domestic players, known for its strong presence in the generic segment. It positions itself by focusing on R&D for new formulations, timely product registrations (CIB&RC), and an extensive distribution network that reaches farmers across various agro-climatic zones in India. It competes with both large MNCs and other prominent Indian agrochemical companies.
MOAT
Extensive Distribution Network: A pan-India presence with a wide network of distributors and dealers reaching deep into rural farming communities, which is crucial for market penetration in India.
Brand Recognition & Farmer Trust: Over years, the company has built trust and brand recognition for several of its products among Indian farmers.
Product Portfolio & Registrations: A diversified product portfolio reduces dependence on a single crop or pest. The ability to successfully register new formulations with the Central Insecticides Board & Registration Committee (CIB&RC) acts as a regulatory barrier to entry.
Formulation Expertise: Strong capabilities in formulating various technical grade pesticides into effective end-use products.
Growth Drivers
Increasing Food Demand: India's growing population and global food security concerns drive demand for higher agricultural output, boosting agrochemical usage.
Declining Arable Land & Need for Productivity: Shrinking per capita arable land necessitates improved yields per acre, making crop protection products essential.
Crop Protection Awareness: Growing awareness among farmers about the economic benefits of pest and disease management.
New Product Launches: Introduction of new and effective formulations/molecules through in-house R&D or collaborations helps expand market share and address evolving pest challenges.
Government Initiatives: Policy support for agriculture (e.g., irrigation, credit, farmer income schemes) can indirectly stimulate demand for agrochemicals.
Risks
Monsoon Dependency: Indian agriculture is heavily reliant on monsoons; inadequate or erratic rainfall directly impacts crop yield and farmer purchasing power, affecting agrochemical demand.
Regulatory Changes: Stringent environmental regulations, bans on certain molecules, or changes in registration policies can significantly impact the business.
Intense Competition & Pricing Pressure: The industry is highly competitive, leading to potential pricing pressure on generic products from both domestic and international players.
Raw Material Price Volatility: Fluctuations in crude oil prices and the availability/cost of key chemical intermediates can impact production costs and margins.
Counterfeit Products: The prevalence of spurious agrochemicals in the market poses a threat to legitimate sales and brand reputation.
Pest Resistance: Evolving pest and disease resistance requires continuous R&D and introduction of new molecules, incurring significant costs.
Management & Ownership
Dhanuka Agritech is promoted by the Dhanuka family, who maintain a significant ownership stake in the company, a common characteristic of many Indian businesses. The management team, often comprising family members and experienced professionals, is generally seen as having deep domain knowledge of the Indian agrochemical sector and a long-term vision for the business. The promoter-led structure typically provides stability and strategic direction, often focusing on sustainable growth within the agricultural ecosystem.
Outlook
Dhanuka Agritech is an established player in the Indian agrochemical sector with a strong distribution network and a diversified product portfolio. Its future performance is closely linked to the health of Indian agriculture, particularly monsoon patterns and farmer prosperity. While it benefits from the structural demand for crop protection products driven by food security needs and increasing farmer awareness, it faces inherent risks from regulatory changes, intense competition, and raw material price volatility. The company's ability to consistently introduce new, effective formulations and expand its market reach, particularly in high-growth segments, will be key to sustaining growth amidst these challenges. The outlook remains balanced, reflecting its foundational strengths tempered by sector-specific dependencies and competitive dynamics.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 393 | 371 | 369 | 618 | 403 | 368 | 494 | 654 | 445 | 442 |
| Other Income | 8 | 15 | 7 | 6 | 7 | 15 | 7 | 11 | 7 | 11 |
| Total Income | 401 | 386 | 376 | 624 | 411 | 384 | 501 | 665 | 452 | 453 |
| Total Expenditure | 342 | 293 | 325 | 476 | 341 | 288 | 422 | 495 | 370 | 332 |
| Operating Profit | 59 | 93 | 50 | 147 | 69 | 95 | 79 | 170 | 83 | 121 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 4 | 5 | 5 | 10 | 13 | 13 | 12 | 13 | 13 | 17 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 54 | 87 | 45 | 137 | 56 | 81 | 66 | 157 | 68 | 102 |
| Provision for Tax | 8 | 21 | 12 | 35 | 10 | 22 | 17 | 39 | 13 | 26 |
| Profit After Tax | 46 | 65 | 33 | 102 | 45 | 59 | 49 | 118 | 55 | 76 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 46 | 65 | 33 | 102 | 45 | 59 | 49 | 118 | 55 | 76 |
| Adjusted Earnings Per Share | 9.9 | 14.3 | 7.2 | 22.3 | 10 | 12.9 | 10.7 | 26.1 | 12.2 | 16.7 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 785 | 829 | 883 | 963 | 1006 | 1120 | 1387 | 1478 | 1700 | 1759 | 2035 | 2035 |
| Other Income | 6 | 13 | 18 | 16 | 21 | 25 | 34 | 34 | 45 | 35 | 36 | 36 |
| Total Income | 791 | 841 | 901 | 979 | 1027 | 1145 | 1421 | 1511 | 1745 | 1794 | 2071 | 2071 |
| Total Expenditure | 653 | 689 | 713 | 796 | 860 | 947 | 1118 | 1214 | 1421 | 1431 | 1619 | 1619 |
| Operating Profit | 138 | 152 | 187 | 182 | 167 | 199 | 303 | 297 | 324 | 362 | 453 | 453 |
| Interest | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 5 | 5 |
| Depreciation | 6 | 6 | 15 | 14 | 12 | 16 | 15 | 16 | 18 | 41 | 55 | 55 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 129 | 145 | 172 | 167 | 154 | 181 | 285 | 278 | 303 | 319 | 392 | 393 |
| Provision for Tax | 23 | 38 | 50 | 41 | 41 | 39 | 74 | 69 | 69 | 80 | 95 | 95 |
| Profit After Tax | 106 | 107 | 122 | 126 | 113 | 141 | 211 | 209 | 234 | 239 | 297 | 298 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 106 | 107 | 122 | 126 | 113 | 141 | 211 | 209 | 234 | 239 | 297 | 298 |
| Adjusted Earnings Per Share | 78.4 | 21.5 | 24.8 | 25.7 | 23.7 | 29.7 | 45.2 | 44.8 | 51.2 | 52.5 | 65.9 | 65.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 16% | 11% | 13% | 10% |
| Operating Profit CAGR | 25% | 15% | 18% | 13% |
| PAT CAGR | 24% | 12% | 16% | 11% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -36% | 11% | 3% | 5% |
| ROE Average | 22% | 22% | 24% | 23% |
| ROCE Average | 29% | 29% | 31% | 30% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 412 | 480 | 522 | 633 | 642 | 708 | 796 | 960 | 1061 | 1256 | 1403 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 21 | 32 | 46 | 39 | 30 | 27 | 59 | 47 | 46 | 45 | 49 |
| Total Current Liabilities | 161 | 144 | 148 | 151 | 163 | 198 | 276 | 304 | 298 | 278 | 349 |
| Total Liabilities | 594 | 657 | 715 | 823 | 835 | 932 | 1131 | 1312 | 1405 | 1579 | 1800 |
| Fixed Assets | 70 | 133 | 138 | 131 | 117 | 117 | 167 | 159 | 165 | 322 | 489 |
| Other Non-Current Assets | 75 | 73 | 74 | 115 | 124 | 148 | 106 | 199 | 345 | 231 | 163 |
| Total Current Assets | 449 | 450 | 503 | 577 | 594 | 666 | 858 | 955 | 896 | 1026 | 1149 |
| Total Assets | 594 | 657 | 715 | 823 | 835 | 932 | 1131 | 1312 | 1405 | 1579 | 1800 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 4 | 1 | 4 | 11 | 0 | 25 | 1 | 1 | 3 | 1 |
| Cash Flow from Operating Activities | 110 | 140 | 63 | 138 | 13 | 162 | 231 | 104 | 136 | 134 | 263 |
| Cash Flow from Investing Activities | -70 | -66 | 20 | -111 | 63 | -44 | -127 | -43 | 3 | -81 | -143 |
| Cash Flow from Financing Activities | -38 | -76 | -81 | -20 | -87 | -93 | -129 | -61 | -137 | -57 | -120 |
| Net Cash Inflow / Outflow | 2 | -2 | 3 | 7 | -10 | 25 | -25 | 1 | 2 | -3 | 0 |
| Closing Cash & Cash Equivalent | 4 | 2 | 4 | 11 | 0 | 25 | 1 | 1 | 3 | 1 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 78.42 | 21.45 | 24.83 | 25.71 | 23.66 | 29.71 | 45.21 | 44.85 | 51.23 | 52.46 | 65.88 |
| CEPS(Rs) | 82.75 | 22.63 | 27.86 | 28.6 | 26.26 | 33.15 | 48.46 | 48.34 | 55.09 | 61.36 | 78.18 |
| DPS(Rs) | 4.5 | 6.5 | 0.6 | 5.5 | 0.6 | 12 | 2 | 14 | 2 | 14 | 2 |
| Book NAV/Share(Rs) | 299.38 | 96.05 | 106.3 | 129.05 | 134.98 | 148.72 | 170.94 | 206.19 | 232.85 | 275.54 | 311.17 |
| Core EBITDA Margin(%) | 15.19 | 15.4 | 16.98 | 14.81 | 12.87 | 13.95 | 17.91 | 16.82 | 15.5 | 17.24 | 18.89 |
| EBIT Margin(%) | 15.22 | 16.13 | 17.25 | 14.97 | 13.65 | 14.65 | 19.14 | 17.92 | 17.01 | 16.94 | 18.02 |
| Pre Tax Margin(%) | 14.92 | 16.01 | 17.14 | 14.88 | 13.56 | 14.51 | 18.95 | 17.7 | 16.83 | 16.78 | 17.79 |
| PAT Margin (%) | 12.23 | 11.82 | 12.18 | 11.24 | 9.91 | 11.36 | 14.01 | 13.32 | 12.98 | 12.59 | 13.47 |
| Cash Profit Margin (%) | 12.91 | 12.47 | 13.66 | 12.5 | 11 | 12.68 | 15.02 | 14.36 | 13.96 | 14.72 | 15.98 |
| ROA(%) | 19.09 | 17.16 | 17.77 | 16.41 | 13.58 | 15.99 | 20.41 | 17.1 | 17.19 | 16.02 | 17.58 |
| ROE(%) | 28.77 | 24.24 | 24.32 | 21.85 | 17.65 | 20.94 | 28 | 23.78 | 23.1 | 20.64 | 22.34 |
| ROCE(%) | 32.98 | 31.96 | 33.93 | 28.79 | 23.8 | 26.41 | 37.86 | 31.83 | 30.2 | 27.73 | 29.41 |
| Receivable days | 76.63 | 76.3 | 67.4 | 63.69 | 68.56 | 67.65 | 58.89 | 61.12 | 63.07 | 65.89 | 66.71 |
| Inventory Days | 84.79 | 73.2 | 79.7 | 76.32 | 66.17 | 67 | 66.21 | 74.79 | 70.25 | 73.3 | 67.59 |
| Payable days | 46.25 | 51.63 | 50.7 | 50.18 | 53 | 53.96 | 51.53 | 60.39 | 62.12 | 60.33 | 46.94 |
| PER(x) | 8.6 | 27.27 | 32.11 | 21.52 | 16.61 | 10.89 | 15.26 | 15.99 | 11.93 | 19.49 | 19.62 |
| Price/Book(x) | 2.25 | 6.09 | 7.5 | 4.29 | 2.91 | 2.18 | 4.04 | 3.48 | 2.62 | 3.71 | 4.15 |
| Dividend Yield(%) | 0.67 | 1.11 | 0.08 | 0.99 | 0.15 | 3.71 | 0.29 | 1.95 | 0.33 | 1.37 | 0.15 |
| EV/Net Sales(x) | 1.18 | 3.54 | 4.43 | 2.81 | 1.88 | 1.36 | 2.32 | 2.26 | 1.64 | 2.65 | 2.88 |
| EV/Core EBITDA(x) | 6.71 | 19.24 | 20.89 | 14.86 | 11.3 | 7.66 | 10.63 | 11.23 | 8.61 | 12.85 | 12.96 |
| Net Sales Growth(%) | 6.32 | 5.57 | 6.58 | 8.98 | 4.49 | 11.36 | 23.87 | 6.51 | 15.05 | 3.43 | 15.73 |
| EBIT Growth(%) | 9.53 | 10.95 | 17.89 | -2.65 | -7.78 | 17.58 | 57.92 | -2.35 | 8.87 | 5.19 | 23.43 |
| PAT Growth(%) | 13.9 | 1.16 | 13.57 | 3.53 | -10.78 | 25.56 | 48.97 | -0.79 | 11.78 | 2.39 | 24.2 |
| EPS Growth(%) | 321.16 | -72.64 | 15.75 | 3.53 | -7.97 | 25.56 | 52.16 | -0.79 | 14.23 | 2.39 | 25.58 |
| Debt/Equity(x) | 0.04 | 0.02 | 0.02 | 0.01 | 0.03 | 0.01 | 0.01 | 0 | 0 | 0 | 0.03 |
| Current Ratio(x) | 2.79 | 3.13 | 3.41 | 3.83 | 3.64 | 3.37 | 3.11 | 3.14 | 3.01 | 3.69 | 3.29 |
| Quick Ratio(x) | 1.6 | 1.93 | 1.62 | 2.47 | 2.38 | 2.11 | 2.04 | 2 | 1.85 | 2.19 | 2.15 |
| Interest Cover(x) | 50.77 | 132.67 | 157.66 | 159.44 | 149.68 | 106.69 | 101.14 | 81.78 | 94.15 | 104.27 | 77.72 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0.01 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.18 | 70.18 | 70.18 | 70.29 | 70.29 | 70.32 | 69.87 | 69.71 | 69.71 | 69.71 |
| FII | 1.34 | 1.49 | 1.53 | 2.01 | 2.16 | 2.19 | 2.66 | 2.3 | 2.13 | 1.93 |
| DII | 18.41 | 18.9 | 19.29 | 19.02 | 18.74 | 18.06 | 17.63 | 18.07 | 18.79 | 19.43 |
| Public | 10.06 | 9.43 | 9 | 8.68 | 8.81 | 9.43 | 9.84 | 9.91 | 9.37 | 8.92 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.2 | 3.2 | 3.2 | 3.17 | 3.17 | 3.17 | 3.15 | 3.14 | 3.14 | 3.14 |
| FII | 0.06 | 0.07 | 0.07 | 0.09 | 0.1 | 0.1 | 0.12 | 0.1 | 0.1 | 0.09 |
| DII | 0.84 | 0.86 | 0.88 | 0.86 | 0.84 | 0.81 | 0.79 | 0.81 | 0.85 | 0.88 |
| Public | 0.46 | 0.43 | 0.41 | 0.39 | 0.4 | 0.42 | 0.44 | 0.45 | 0.42 | 0.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.56 | 4.56 | 4.56 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +16% | +11% | +13% | +10% |
| Operating Profit CAGR | +25% | +15% | +18% | +13% |
| PAT CAGR | +24% | +12% | +16% | +11% |
| Share Price CAGR | -36% | +11% | +3% | +5% |
| ROE Average | +22% | +22% | +24% | +23% |
| ROCE Average | +29% | +29% | +31% | +30% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.18 | 70.18 | 70.18 | 70.29 | 70.29 | 70.32 | 69.87 | 69.71 | 69.71 | 69.71 |
| FII | 1.34 | 1.49 | 1.53 | 2.01 | 2.16 | 2.19 | 2.66 | 2.3 | 2.13 | 1.93 |
| DII | 18.41 | 18.9 | 19.29 | 19.02 | 18.74 | 18.06 | 17.63 | 18.07 | 18.79 | 19.43 |
| Public | 29.82 | 29.82 | 29.82 | 29.71 | 29.71 | 29.68 | 30.13 | 30.29 | 30.29 | 30.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.2 | 3.2 | 3.2 | 3.17 | 3.17 | 3.17 | 3.15 | 3.14 | 3.14 | 3.14 |
| FII | 0.06 | 0.07 | 0.07 | 0.09 | 0.1 | 0.1 | 0.12 | 0.1 | 0.1 | 0.09 |
| DII | 0.84 | 0.86 | 0.88 | 0.86 | 0.84 | 0.81 | 0.79 | 0.81 | 0.85 | 0.88 |
| Public | 1.36 | 1.36 | 1.36 | 1.34 | 1.34 | 1.34 | 1.36 | 1.37 | 1.37 | 1.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4.56 | 4.56 | 4.56 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.